Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Breast 2Head & Neck 1

Conditions

Breast Neoplasms 243Neoplasms 17Neoplasm Metastasis 15Carcinoma, Intraductal, Noninfiltrating 11Breast Diseases 8Advanced Breast Cancer 8Breast Neoplasms, Male 7Breast Carcinoma In Situ 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Arthralgia 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Recurrence 2Patient Compliance 2Osteoporosis 2Obesity 2Multiple Endocrine Neoplasia Type 1 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Vitamin D Deficiency 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1

Interventions

Paclitaxel 95Carboplatin 76pembrolizumab 72Cisplatin 28Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Observation 13Gemcitabine 13Blood Specimen Collection 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Anastrozole × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
32 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04719273 2025-01-08

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Thomas Jefferson University

Phase 2 Active not recruiting
14 enrolled
Gynecologic

Endometrial Neoplasms

NCT02730923 2024-02-13

VICTORIA

Centre Leon Berard

Phase 1/2 Unknown
72 enrolled
Gynecologic

Carcinoma, Endometrial Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡